✦ LIBER ✦

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

✍ Scribed by O. Stål; S. Sullivan; S. Wingren; L. Skoog; L.E. Rutqvist; J.M. Carstensen; B. Nordenskjöld

Book ID: 116166457
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 627 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)00344-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S-phase fraction and survival benefit fr

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer

✍ Stål, O; Skoog, L; Rutqvist, LE; Carstensen, JM; Wingren, S; Sullivan, S; Anders 📂 Article 📅 1994 🏛 Nature Publishing Group 🌐 English ⚖ 964 KB

Adjuvant radiotherapy and chemotherapy i

Adjuvant radiotherapy and chemotherapy in breast cancer

✍ Mr C. S. McArdle; D. Crawford; E. H. Dykes; K. C. Calman; D. Hole; A. R. Russell 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 2 views

Decreased expression of C-erbB-2 and CXC

Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy

✍ Shi-Xin Yang, Wings TY Loo, Louis WC Chow… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 377 KB

HER2 Status and Benefit from Adjuvant Tr

HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

✍ Paik, Soonmyung; Kim, Chungyeul; Wolmark, Norman 📂 Article 📅 2008 🏛 Massachusetts Medical Society 🌐 English ⚖ 164 KB

ERBB2 status and benefit from adjuvant t

ERBB2 status and benefit from adjuvant tamoxifen in ERα-positive postmenopausal breast carcinoma

✍ I Bièche; P Onody; F Lerebours; S Tozlu; K Hacene; C Andrieu; M Vidaud; M Tubian 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 81 KB

No significant predictive value of c- er

No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

✍ Sylvie Rozan; Anne Vincent-Salomon; Brigitte Zafrani; Pierre Validire; Patricia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 325 KB 👁 2 views

To document whether c-erbB-2 over-expression or p53 accumulation in tumour cells was predictive of response to chemo-or radiotherapy, we analyzed a population of patients with breast cancer assigned to neo-adjuvant therapy (median follow-up: 54 months). T2/T3-N0N1b-M0 tumours (329 cases) were treate